CLDI Latest Press Releases

-- July 21, 2026 --

Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers Globe Newswire 8:00 AM

-- July 20, 2026 --

Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 Globe Newswire 4:30 PM

-- July 8, 2026 --

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 Globe Newswire 4:05 PM

-- June 24, 2026 --

Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit Globe Newswire 8:00 AM

-- June 23, 2026 --

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors Globe Newswire 8:00 AM

-- June 16, 2026 --

Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study Globe Newswire 8:00 AM

-- June 8, 2026 --

Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026 Globe Newswire 8:00 AM

-- May 26, 2026 --

Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting Globe Newswire 8:00 AM

-- May 22, 2026 --

Calidi Biotherapeutics Provides Required NYSE American Disclosure Globe Newswire 6:00 PM

-- May 14, 2026 --

Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights Globe Newswire 4:10 PM

-- May 13, 2026 --

Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston Globe Newswire 8:00 AM

-- April 29, 2026 --

Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI Globe Newswire 8:00 AM

-- April 21, 2026 --

Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 Globe Newswire 8:00 AM

-- April 20, 2026 --

Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 Globe Newswire 8:00 AM

-- April 15, 2026 --

Calidi Biotherapeutics Announces Participation in RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms Globe Newswire 8:00 AM

-- April 14, 2026 --

Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavk, Iceland on April 28th Highlighting the RedTail Platform's Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy Globe Newswire 8:00 AM

-- April 7, 2026 --

Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform's Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy Globe Newswire 8:00 AM

-- April 2, 2026 --

Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 Globe Newswire 8:00 AM

-- April 1, 2026 --

Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 Globe Newswire 8:00 AM

-- March 27, 2026 --

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights Globe Newswire 4:25 PM

-- March 24, 2026 --

Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials Globe Newswire 8:00 AM

-- March 12, 2026 --

Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing Globe Newswire 8:00 AM

-- March 9, 2026 --

Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option Globe Newswire 8:50 PM

-- March 6, 2026 --

Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering Globe Newswire 8:30 AM

-- March 5, 2026 --

Calidi Biotherapeutics Announces Proposed Public Offering Globe Newswire 5:57 PM